Share this article and save a life!
35 is the new 40 for breast cancer screening, thanks to AI.
Just yesterday, the NCCN dropped new guidelines that could reshape how we approach breast cancer prevention. They’re now recommending AI-based mammogram risk assessment starting at age 35, not 40.
The threshold? A 1.7% five-year risk score.
This isn’t theoretical. Beth Israel Deaconess is already implementing Clairity Breast AI tools. Invision Sally Jobe in Colorado goes live this spring. Emory Healthcare follows this summer.
The evidence is compelling:
• Swedish trial (January 2026): AI cut interval cancers by 12%
• Detection rates jumped from 74% to 81%
• Radiologist workload dropped 44%
• Google’s NHS study: AI found 24% more invasive cancers
• False positive callbacks fell 39%
Here’s what fascinates me: We’re not replacing radiologists, we’re amplifying their capabilities. The PRISM trial calls AI a “co-pilot” for radiologists. That 44% workload reduction means more time for complex cases, biopsies, and patient interaction.
But I keep wondering about access. Will this technology reach community clinics and FQHCs serving vulnerable populations? Or will we create another tier of healthcare inequality?
The technology exists. The guidelines are clear. Major centers are moving fast.
The question isn’t whether AI will transform breast cancer screening. It’s whether we’ll ensure equitable access to these life-saving advances.
Because finding cancer five years earlier shouldn’t depend on your zip code.
♻️ Repost if earlier breast cancer screening should be accessible to all women
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
